22-LEUK-21-NP (CABL001AUS08): A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase-Chronic Myelogenous Leukemia (ASC2ESCALATE)

Grants and Contracts Details

StatusActive
Effective start/end date2/3/23 → 12/31/28

Funding

  • Novartis (domestic): $180,312.00